Sebia SA
French maker of electrophoresis systems that labs use to test blood proteins and diagnose disorders.
On the record
Checkpoint: Next FDA or CE clearance expected, continuing Sebia's pattern of one to two per year
The call
Sebia keeps its lead through decades of clearances and lab habit, not through any AI product, while mass spectrometry and interpretive software remain research projects rather than shipped rivals.
Sebia is a French company that makes machines and tests for detecting proteins in blood, used mainly to spot blood cancers and other diseases. It is hard to replace because hospitals have used its machines for decades, switching would be expensive and risky, and the company has gotten special government permission to sell each new test. Thermo Fisher, Danaher, Roche, and Siemens could try to compete, but none have shipped a product that actually took customers away yet. The one thing that could change this is if doctors start using a different technology called mass spectrometry instead of Sebia's electrophoresis machines to test for the same diseases, but that is still years away and not yet approved for sale.
Why
01
AI pressure: Research-stage ML tools for electrophoresis interpretation (academic, unshipped). No FDA-cleared AI reading layer exists yet for this test; a rival shipping one first could threaten Sebia's reference-standard status over time. Could AI do the core job? Unlikely.
02
Bigger players: Thermo Fisher, Danaher/Beckman Coulter, Roche Diagnostics, Siemens Healthineers. All are bigger diagnostics players but none has shipped a cleared electrophoresis analyzer that has taken lab placements from Sebia. Could a giant copy it? No, they are blocked.
03
What protects it. Fifty-plus years as the reference method, per-assay FDA/CE clearances, and hospital labs locked into its workflow and instruments.
What would change this call
FDA clearance of a mass-spectrometry-based M-protein monitoring product from any commercial vendor. Would show a substitute modality reaching market that could erode Sebia's myeloma-monitoring franchise.
Thermo Fisher, Danaher, Roche, or Siemens ships an FDA-cleared capillary-electrophoresis analyzer with a comparable assay menu. Would show a direct incumbent finally challenging Sebia's reference-standard position.
Sebia or a rival announces an FDA-cleared AI interpretive layer for electrophoresis results. Would show whether Sebia keeps pace or a competitor overtakes it on interpretive technology.
Thermo Fisher, Danaher, Roche, or Siemens ships an FDA-cleared capillary-electrophoresis analyzer with a comparable assay menu. Would show a direct incumbent finally challenging Sebia's reference-standard position.
Sebia or a rival announces an FDA-cleared AI interpretive layer for electrophoresis results. Would show whether Sebia keeps pace or a competitor overtakes it on interpretive technology.
Key numbers
- Valued at about EUR 5 to 5.5 billion on roughly $326M revenue
- Sells in 140+ countries through 23 direct subsidiaries
- Founded 1967, over 50 years as clinical reference method
Named risks
- Active French appellate litigation from 2023 through 2025 with undisclosed nature.
- Mass-spectrometry-based M-protein monitoring could substitute electrophoresis long-term.
- No confirmed AI-branded interpretive software shipped, leaving a roadmap gap versus future entrants.
- Valuation jump from EUR 2 billion to EUR 5.5 billion in eight years raises sustainability questions on revenue/EBITDA multiple.
- Inconsistent public revenue and headcount figures complicate independent verification of financial health.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Helena Biosciences | contesting | V8/V8 UltraCE validated as alternative to Sebia Capillarys in peer-reviewed study, 2025 |
| The Binding Site | contesting | Freelite free light chain assay directly compared against Sebia's FLC assay in clinical studies |
| Bio-Rad Laboratories | contesting | Named alongside Sebia as key vendor in global electrophoresis market report, Dec 2022 |
| Thermo Fisher, Danaher, Roche, Siemens Healthineers | losing to | None have shipped an FDA-cleared rival electrophoresis analyzer taking share as of 2026 |
| Mass-spectrometry M-protein monitoring (Mayo Clinic research) | gaining on | Research-stage substitute for myeloma monitoring, not yet FDA-cleared or commercially placed as of 2026 |
Questions people ask
- Who owns Sebia now in 2026?
- Warburg Pincus closed a significant minority stake investment in Sebia by April 2026, with existing shareholders CVC Funds, Tethys Invest and CDPQ (La Caisse) remaining investors alongside a subsidiary of the Abu Dhabi Investment Authority, per Warburg Pincus's April 16, 2026 closing announcement.
- Is Sebia profitable?
- Sebia's own revenue and EBITDA figures beyond 2021 are not publicly disclosed. The company's French legal entity reported EUR 212 million statutory revenue in 2022. Its 2025 valuation of EUR 5 to 5.5 billion implies strong profitability, but no confirmed current EBITDA figure is public as of 2026.
- Could AI replace Sebia's electrophoresis business?
- Not yet as of 2026. A peer-reviewed scoping review on machine learning for interpreting protein electrophoresis in multiple myeloma was published July 2026, but remains research-stage. No FDA-cleared AI interpretive layer or mass-spec substitute has shipped commercially to challenge Sebia's regulated hardware and reagent installed base.
- Who is Sebia's biggest competitor?
- Sebia's closest direct rivals in capillary electrophoresis are Helena Biosciences (V8/V8 UltraCE) and The Binding Site (Freelite assay), both validated in clinical studies as alternatives, though neither has taken meaningful market share from Sebia's reference-standard installed base as of 2026.
- How much is Sebia worth in 2026?
- Sebia was valued around EUR 5 to 5.5 billion (about USD 6.4 billion) during the September to October 2025 competition among Blackstone, Warburg Pincus and Nordic Capital for a stake, up from roughly EUR 2 billion when CVC and Tethys Invest bought a majority stake in October 2017.
- What is Sebia's flagship product?
- Sebia's core platforms are the CAPILLARYS capillary electrophoresis analyzers and Hydrasys/Hydragel gel electrophoresis systems, used for protein electrophoresis, immunofixation, hemoglobinopathy screening and free light chain assays for multiple myeloma diagnosis and monitoring.
Timeline
- 2026-04-16Warburg Pincus closes minority stake deal; CVC, Tethys Invest, CDPQ, ADIA co-invest
- 2025-12-09EU Commission clears Warburg Pincus acquisition of Sebia stake
- 2025-10-16Warburg Pincus enters exclusive talks for significant minority stake in Sebia
- 2025-09-25Blackstone, Warburg Pincus, Nordic Capital vie for stake at EUR 5 to 5.5 billion valuation
- 2024-04-05Sebia receives FDA 510(k) clearance for CAPILLARYS 3 DBS newborn screening device
- 2023-12-20Sebia launches Hydrashift 2/4 daratumumab assay for myeloma drug monitoring
- 2022Sebia acquires Zeus Scientific
- 2021Sebia acquires Orgentec Diagnostika, Corgenix and Arotec
- 2017-10CVC Capital Partners and Tethys Invest acquire majority stake, valuation near EUR 2 billion
- 1967Sebia founded in France
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Société SEBIA à LISSES (2026-07-15)
- Sebia and Warburg Pincus Partner to Drive Innovation in Diagnostics (2025-10-16)
- Les derniers chiffres, actualités et études de marché sur Sebia (2023-10-16)
- Blackstone, Warburg Said to Vie for CVC-Backed Sebia Stake (2025-09-25)
- EU Commission clears acquisition of Sebia by Warburg Pincus (2025-12-08)
- Warburg Pincus LinkedIn, closing announcement (2026-04-16)
- SEBIA - Overview, News & Similar companies (2026-07-12)
- Sebia S.A. Asset Profile
- Evaluation of a Capillary Electrophoresis System for the Separation of Proteins
- Chiffre d'affaires, statuts, extrait d'immatriculation (2026-04-13)
- Management and Employees List
- Sebia Receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices (2024-04-05)